...
首页> 外文期刊>Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association >The Hannover Dialysis Outcome study: comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit.
【24h】

The Hannover Dialysis Outcome study: comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit.

机译:汉诺威透析结果研究:在重症监护病房中对急性肾损伤患者进行标准透析和强化透析的比较。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Increasing the dose of renal replacement therapy has been shown to improve survival in critically ill patients with acute kidney injury (AKI) in several smaller European trials. However, a very recent large multicentre trial in the USA could not detect an effect of dose of renal replacement therapy on mortality. Based on those studies, it is not known whether a further increase in dialysis dose above and beyond the currently employed doses would improve survival in patients with AKI. We therefore aimed to assess mortality and renal recovery of patients with AKI receiving either standard (SED) or intensified extended dialysis (IED) therapy in the intensive care unit. METHODS: A prospective randomized parallel group study was conducted in seven intensive care units of a tertiary university hospital. Pre-existing chronic kidney disease was an exclusion criterion. A total of 156 patients (570 screened) with AKI requiring renal replacement therapy were randomly assigned to receive standard dialysis [dosed to maintain plasma urea levels between 120 and 150 mg/dL (20-25 mmol/L)] or intensified dialysis [dosed to maintain plasma urea levels <90 mg/dL (<15 mmol/L)]. Outcome measures were survival at Day 14 (primary) and survival and renal recovery at Day 28 (secondary) after initiation of renal replacement therapy. RESULTS: Treatment intensity differed significantly (P < 0.01 for plasma urea and administered dose). No differences between intensified and standard treatment were seen for survival by Day 14 (70.4% versus 70.7%) or Day 28 (55.6% versus 61.3%), or for renal recovery amongst the survivors by Day 28 (60.0% versus 63.0%). CONCLUSIONS: Although this study cannot deliver a definitive answer, it suggests that increasing the dose of extended dialysis above the currently recommended dose might neither reduce mortality nor improve renal recovery in critically ill patients, mainly septic patients, with AKI.
机译:背景:在一些较小的欧洲试验中,增加肾脏替代疗法的剂量已显示可改善重症急性肾损伤(AKI)患者的生存率。但是,最近在美国进行的一项大型多中心试验未能检测到肾脏替代治疗剂量对死亡率的影响。基于这些研究,尚不清楚在目前使用的剂量之上和之外进一步增加透析剂量是否会改善AKI患者的生存率。因此,我们旨在评估在重症监护病房接受标准(SED)或强化扩展透析(IED)治疗的AKI患者的死亡率和肾脏恢复。方法:在一家三级大学医院的七个重症监护室进行了一项前瞻性随机平行分组研究。既往已存在的慢性肾脏病是一项排除标准。总共156名需要肾脏替代治疗的AKI患者(筛查了570名)被随机分配接受标准透析[维持血浆尿素水平在120至150 mg / dL(20-25 mmol / L)之间]或加强透析[给药维持血浆尿素水平<90 mg / dL(<15 mmol / L)]。结果指标是开始肾脏替代治疗后第14天(主要)的存活率和第28天(次要)的存活率和肾脏恢复。结果:治疗强度差异显着(血浆尿素和给药剂​​量P <0.01)。在第14天(70.4%对70.7%)或第28天(55.6%对61.3%)的存活率,或在第28天存活者之间的肾恢复(60.0%对63.0%),强化治疗与标准治疗之间无差异。结论:尽管这项研究无法提供确切的答案,但它表明,将延长透析剂量增加至当前推荐剂量以上可能不会降低重症患者(主要是脓毒症患者)的死亡率,也不会改善其肾脏恢复。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号